Serological Study of Fascioliasis Using Indirect ELISA in Gorgan City, Golestan Province, Northern Iran
Background: Fascioliasis is a neglected zoonotic disease, caused by Fasciola species in human and livestock. We aimed to detect the seroprevalence of human fascioliasis Gorgan City, Golestan Province, northern Iran using ELISA method in 2017.
Methods: Overall, 612 serum samples were analyzed. A relevant questionnaire for demographic data was obtained for all cases. An indirect ELISA test was used to detect IgG antibodies against Fasciola in the sera. The data analysis was performed employing SPSS program version 21.
Results: Eleven cases (1.79%) were seropositive for fascioliasis. The seroprevalence of fascioliasis was 1.9% and 1.1% among males and females, respectively. There was no statistically significant association between the fascioliasis and analyzed variables such as sex, age, residence, job, education, etc.
Conclusion: This study was conducted only on the people referring to the Reference Laboratory of Gorgan. It cannot be distributed to the whole city. Thus, due to importance of the disease, finding the seroprevalence of fascioliasis in a comprehensive survey in Golestan Province should be accounted in further studies.
2. Ashrafi K, Bargues MD, O'Neill S, et al. Fascioliasis: a worldwide parasitic disease of importance in travel medicine. Travel Med Infect Dis. 2014; 12(6):636-49.
3. Rokni M. Helminth-Trematode: Fasciola hepatica and F. gigantica. In: Motarjemi Y, editor. Encyclopedia of Food Safety. 1st ed. Amster-dam: Elsevier/Academic Press; 2015. p. 140-5.
4. Bozorgomid A, Nazari N, Rokni MB,et al. Epidemiology of fascioliasis in Kermanshah Province, western Iran. Iran J Public Health. 2018; 47(7):967-972.
5. Mas-Coma S, Valero MA, Bargues MD. Fascioliasis, in Digenetic Trematodes, R Toledo,Fried, B, Editors., Springer International Publishing: Cham; 2019. p. 71-103.
6. Ashrafi K. The status of human and animal fascioliasis in Iran: A narrative review article. Iran J Parasitol. 2015; 10(3):306-328.
7. Saebi E, Parasitic Diseases in Iran (in Persian). Tehran, Iran: Ayeezh; 2009.
8. Rokni MB, Bozorgomid A, Heydarian P, et al. Molecular Evidence of Human Fasciolosis Due to Fasciola gigantica in Iran: A Case Report. Iran J Public Health. 2018; 47(5):750-4.
9. Fathi S, Ghasemikhah R, Mohammadi R, et al. Seroprevalence of hydatidosis in people referring to Reference laboratory of Gorgan, Golestan Province, northern Iran 2017. Iran J Parasitol. 2019; 14(3) :436–443.
10. Aryaeipour M, Eshrat Beigom K, Heidari Z, et al. Serological study of human fasciolosis in patients referring to the School of Public Health, Tehran University of Medical Sciences, Tehran, Iran during 2008–2014. Iran J Parasitol. 2015; 10(4):517-22.
11. Rokni MB, Massoud J, O’Neill SM, et al. Diagnosis of human fasciolosis in the Gilan province of Northern Iran: application of cathepsin L-ELISA. Diagn Microbiol Infect Dis. 2002; 44(2):175-9.
12. Saberinasab M, Mohebali M, Molawi G, et al. Seroprevalence of human fascioliasis using indirect ELISA in Isfahan district, central Iran in 2013. Iran J Parasitol. 2014; 9(4):461-5.
13. Sarkari B, Ghobakhloo N, Moshfea A, et al. Seroprevalence of human fasciolosis in a new-emerging focus of fasciolosis in Yasuj district, southwest of Iran. Iran J Parasitol. 2012; 7(2):15-20.
14. Asadian S, Mohebali M, Mahoudi M, et al. Seroprevalence of human fascioliasis in Meshkin-Shahr district, Ardabil Province, northwestern Iran in 2012. Iran J Parasitol. 2013; 8(4):516-21.
15. Ashrafi K, Saadat F, O’Neill S, et al. The endemicity of human fascioliasis in Guilan province, northern Iran: the baseline for implementation of control strategies. Iran J Public Health. 2015; 44(4):501-11.
16. Heydarian P, Ashrafi K, Mohebali M, et al. Seroprevalence of human fasciolosis in Lorestan Province, western Iran, in 2015–16. Iran J Parasitol. 2017; 12(3):389-97.
17. Manouchehri Naeini K, Mohammad Nasiri F, Rokni MB, et al. Seroprevalence of human fascioliasis in Chaharmahal and Bakhtiyari Province, Southwestern Iran. Iran J Public Health. 2016; 45(6):774-80.
18. Abdi J, Naserifar R, Rostami Nejad M, et al. New features of fascioliasis in human and animal infections in Ilam province, Western Iran. Gastroenterol Hepatol Bed Bench. 2013; 6(3):152-5.
19. Kheirandish F, Kayedi MH, Ezatpour B, et al. Seroprevalence of human fasciolosis in Pirabad, Lorestan Province, Western Iran. Iran J Parasitol. 2016; 11(1):24-9.
20. Cengiz ZT, Yilmaz H, Dulger AC, et al. Seroprevalence of human fascioliasis in Van province, Turkey. Turk J Gastroenterol. 2015; 26(3)259-62.
21. Ozturhan H, Emekdaş G, Sezgin O, et al. Seroepidemiology of Fasciola hepatica in Mersin province and surrounding towns and the role of family history of the Fascioliasis in the transmission of the parasite. Turk J Gastroenterol. 2009; 20(3):198-203.
22. Martínez-Barbabosa I, Gutiérrez-Quiroz M, Romero-Cabello R, et al. Seroepidemiology of fascioliasis in school children in Mexico City. Rev Biomed. 2006; 17:251-7.
23. González LC, Esteban JG, Bargues MD, et al. Hyperendemic human fascioliasis in Andean valleys: An altitudinal transect analysis in children of Cajamarca province, Peru. Acta Trop. 2011; 120(1-2):119-29.
24. Esteban J-g, Gonzalez C, Curtale F, et al. Hyperendemic fascioliasis associated with schistosomiasis in villages in the Nile Delta of Egypt. Am J Trop Med Hyg. 2003; 69(4):429-37.
25. Esteban J-G, Flores A, Angles R, et al. High endemicity of human fascioliasis between Lake Titicaca and La Paz valley, Bolivia. Trans R Soc Trop Med Hyg. 1999; 93(2):151-6.
26. Moghaddam A, Massoud J, Mahmoodi M, et al. Human and animal fascioliasis in Mazandaran province, northern Iran. Parasitol Res. 2004; 94(1):61-9.
27. Ashrafi K, Valero M, Forghan-Parast K, et al. Potential Transmission of Human Fascioliasis Through Traditional Local Foods, in Northern Iran. Iran J Public Health. 2006; 35(2): 49-56.
|Issue||Vol 15 No 3 (2020)|
|Seroprevalence Human fascioliasis Serodiagnosis Iran|
|Rights and permissions|
|This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.|